About Enthera
Enthera is a company based in Milano (Italy) founded in 2016 by Gabriella Camboni.. Enthera has raised $45.91 million across 3 funding rounds from investors including AbbVie, Sofinnova Partners and T1D Fund. Enthera offers products and services including Ent001 and Monoclonal Antibodies. Enthera operates in a competitive market with competitors including Moderna, Aclaris Therapeutics, Horizon Therapeutics, Forge Biologics and argenx, among others.
- Headquarter Milano, Italy
- Founders Gabriella Camboni
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Enthera Srl
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$45.91 M (USD)
in 3 rounds
-
Latest Funding Round
$8.49 M (USD), Series A
Jan 28, 2021
-
Investors
AbbVie
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enthera
Enthera offers a comprehensive portfolio of products and services, including Ent001 and Monoclonal Antibodies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Antibody targeting TMEM219 for Ulcerative Colitis treatment
Libraries of antibodies for IGFBP3/TMEM219 pathway in autoimmune diseases
Unlock access to complete
Unlock access to complete
Funding Insights of Enthera
Enthera has successfully raised a total of $45.91M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $8.49 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $8.5M
-
First Round
First Round
(01 Jun 2018)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series A - Enthera | Valuation | Roche | |
| Jul, 2020 | Amount | Series A - Enthera | Valuation | Sofinnova Partners , AbbVie | |
| Jun, 2018 | Amount | Seed - Enthera | Valuation | T1D Fund |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Enthera
Enthera has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, Sofinnova Partners and T1D Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location | |
|
Companies developing T1D products are funded through venture philanthropy.
|
Founded Year | Domain | Location | |
|
Corporate-backed venture capital firm focused on the healthcare sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Enthera
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Enthera
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Enthera Comparisons
Competitors of Enthera
Enthera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Aclaris Therapeutics, Horizon Therapeutics, Forge Biologics and argenx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Enthera
Frequently Asked Questions about Enthera
When was Enthera founded?
Enthera was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is Enthera located?
Enthera is headquartered in Milano, Italy.
Who is the current CEO of Enthera?
Giovanni Amabile is the current CEO of Enthera.
Is Enthera a funded company?
Enthera is a funded company, having raised a total of $45.91M across 3 funding rounds to date. The company's 1st funding round was a Seed of $4.58M, raised on Jun 01, 2018.
What does Enthera do?
Enthera was founded in 2016 in Milano, Italy, where biotherapeutics targeting auto-immune disorders, including type-1 diabetes, are developed. Focus is placed on the IGFBP3TMEM219 pathway, which influences stem cell apoptosis in these conditions. A proprietary discovery engine is utilized to generate libraries of monoclonal antibodies and fusion proteins. Operations center on advancing pipeline products for therapeutic applications in the biotechnology sector.
Who are the top competitors of Enthera?
Enthera's top competitors include Moderna, argenx and Forge Biologics.
What products or services does Enthera offer?
Enthera offers Ent001 and Monoclonal Antibodies.
Who are Enthera's investors?
Enthera has 5 investors. Key investors include AbbVie, Sofinnova Partners, T1D Fund, Roche, and Banor.